{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T11:17:28Z","timestamp":1782040648441,"version":"3.54.5"},"reference-count":39,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to develop a prostatic pharmacokinetic model of ceftazidime and suggest more effective dosing strategy for the bacterial prostatitis, based on a site\u2010specific pharmacokinetic and pharmacodynamic perspective. Subjects were prostatic hyperplasia patients prophylactically receiving a 0.5\u2010h infusion of 1.0 g or 2.0 g ceftazidime before transurethral resection of the prostate. Plasma and prostate samples were premeditatedly collected after the administration and the concentrations were measured by high\u2010performance liquid chromatography. The prostate tissue\/plasma ratio in area under the drug concentration\u2010time curve was approximately 0.476. The prostatic population pharmacokinetic model incorporated creatinine clearance (CL<jats:sub>cr<\/jats:sub>) into ceftazidime clearance was developed, and adequately predicted prostate tissue concentrations by diagnostic scatter plots and visual predictive checks. Aiming for a bactericidal target of 70% of time above minimum inhibitory concentration (T &gt; MIC) in prostate tissue, 2.0 g twice daily achieved \u226590% expected probability against main pathogens like <jats:italic>Escherichia coli<\/jats:italic> and <jats:italic>Proteus<\/jats:italic> species in patients regardless of renal function (CL<jats:sub>cr<\/jats:sub> = 60 and 90 mL\/min). However, since the expected probability of attaining the bactericidal target of 0.5\u2010h infusion dosing regimen did not achieve 90% against <jats:italic>Pseudomonas aeruginosa<\/jats:italic> in patients with CL<jats:sub>cr<\/jats:sub> = 60 and 90 mL\/min, 4\u2010h infusion dosing regimen of 2.0 g three times daily (6 g\/day) might be required for empirical treatment. Based on site\u2010specific simulations, the present study provides more effective dosing strategy for bacterial prostatitis.<\/jats:p>","DOI":"10.1002\/jcph.6119","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T08:16:00Z","timestamp":1724660160000},"page":"121-131","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prostatic Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime: Dosing Strategy for Bacterial Prostatitis"],"prefix":"10.1002","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1174-0787","authenticated-orcid":false,"given":"Tetsushu","family":"Onita","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacotherapy Hiroshima University Hiroshima Japan"},{"name":"Department of Pharmacy Shimane University Hospital Izumo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kogenta","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Nakamura Urology Clinic Owariasahi Japan"},{"name":"Aichi Medical University School of Medicine Nagakute Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genya","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Asahi Rosai Hospital Owariasahi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Shimane University Hospital Izumo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Tamaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Shimane University Hospital Izumo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Shimane University Hospital Izumo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Naora","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Shimane University Hospital Izumo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Morikawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacotherapy Hiroshima University Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9349-4067","authenticated-orcid":false,"given":"Kazuro","family":"Ikawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacotherapy Hiroshima University Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Sagent Pharmaceuticals.Drug label information: ceftazidime injection powder for solution. Accessed June 1 2024.https:\/\/dailymed.nlm.nih.gov\/dailymed\/getFile.cfm?setid=112c5457\u20108d71\u201049f5\u2010b531\u20109761d7d38c93&type=pdf"},{"key":"e_1_2_9_3_1","unstructured":"Wockhardt UK Ltd.Summary of product characteristics. ceftazidime 2g powder for solution for injection or infusion. Accessed June 1 2024.https:\/\/www.medicines.org.uk\/emc\/product\/6347\/smpc\/print"},{"key":"e_1_2_9_4_1","unstructured":"GlaxoSmithKline Japan Ltd.Modacin prescribing information. Accessed June 1 2024.https:\/\/image.packageinsert.jp\/pdf.php?mode=1&yjcode=6132418F1041"},{"key":"e_1_2_9_5_1","first-page":"221","volume-title":"The JAID\/JSC Guide to Clinical Management of Infectious Diseases","author":"The Japanese Association for Infectious Disease\/Japanese Society of Chemotherapy","year":"2019"},{"key":"e_1_2_9_6_1","unstructured":"BonkatG BartolettiR Bruy\u00e8reF et\u00a0al.European Association of Urology guidelines on urological infection. Accessed June 1 2024.https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full\u2010guideline\/EAU\u2010Guidelines\u2010on\u2010Urological\u2010Infections\u20102024.pdf"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/652861"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1086\/321854"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02857.x"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.08.014"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04117.x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15612"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1800"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2015.04.015"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2019.08.019"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2017.08.005"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.11.001"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.24.3.333"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(99)70265-9"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2521081400"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/10937400802545060"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2003.11.003"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1198-743x.2001.00295.x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1086\/344653"},{"key":"e_1_2_9_27_1","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. The database of MIC and zone diameter distributions. Accessed June 1 2024.http:\/\/mic.eucast.org\/Eucast2\/"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/16.6.757"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01915.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00430-09"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2842"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-023-02167-9"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/0897190021989931"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1991.tb04302.x"},{"key":"e_1_2_9_35_1","unstructured":"Allergen Inc.Drug label information: AVYCAZ ceftazidime\u2010avibactam powder for solution. Accessed June 24 2024.https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=d9c2803f\u2010dc9c\u20104b19\u2010b4a3\u20108303bc8c15fd"},{"key":"e_1_2_9_36_1","first-page":"322","volume-title":"The Sanford guide to antimicrobial therapy","author":"Gilbert DN","year":"2021"},{"key":"e_1_2_9_37_1","volume-title":"M100: Performance Standards for Antimicrobial Susceptibility Testing","author":"Clinical and Laboratory Standards Institute","year":"2024"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-081X(199810)19:7<473::AID-BDD125>3.0.CO;2-M"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm476"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1159\/000074526"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.6119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T04:42:24Z","timestamp":1735533744000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.6119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1002\/jcph.6119"],"URL":"https:\/\/doi.org\/10.1002\/jcph.6119","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,26]]},"assertion":[{"value":"2024-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}